FDA
-
-
-
-
-
-
-
Ryvu Therapeutics reports financial results for 2020
-
-
-
-
-
-
-
Gilead shares slide after FDA knocks back rheumatoid arthritis drug
-
-
-
-
-
-
-
New Analyses of Phase 2 EQUATOR Clinical Program Support Durable Efficacy of Filgotinib in Psoriatic Arthritis
-
-
-
-
-
-
-
New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile
-
-
-
-
-
-
-
Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis
-
-
-
-
-
-
-
Galapagos NV (GLPG), Servier Report Complete Enrollment of Global ROCCELLA Phase 2 Clinical Trial with GLPG1972/S201086
-
-
-
-
-
-
-
Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)
-
330,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

